Browsing Tag
Stelara
7 posts
NYSE: JNJ Q4 earnings rise 49% to $2.10 EPS; oncology and neuroscience lead portfolio momentum
Johnson & Johnson posts $94.2B in 2025 revenue and sets $100.5B FY26 target. Find out what’s driving growth and how STELARA’s erosion could impact momentum.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.
Biocon Biologics reports positive Phase 3 results for Yesintek, biosimilar to Ustekinumab
Biocon Biologics Ltd., a global leader in biosimilar medicines and a subsidiary of India’s pioneering biopharmaceutical giant Biocon…
EMA accepts MAA for Dong-A ST’s Stelara biosimilar, DMB-3115
Dong-A ST, the South Korean pharmaceutical company, has received confirmation from the European Medicine Agency (EMA) of the…
Biocon Biologics signs licensing deal for two biosimilars with Yoshindo
Biocon Ltd. said that its subsidiary Biocon Biologics has signed an out-licensing agreement with Japanese pharma company Yoshindo…
Bio-Thera, Hikma Pharmaceuticals sign $150m licensing deal for BAT2206
Chinese biopharma company Bio-Thera Solutions has signed a commercialization and license deal worth up to $150 million with…
Janssen bags Stelara FDA approval for ulcerative colitis treatment
Stelara FDA approval for ulcerative colitis treatment : The Janssen Pharmaceutical Companies of Johnson & Johnson has bagged…